STAT Plus: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon
Adam’s Biotech Scorecard
Adam’s Biotech Scorecard is a subscriber-only newsletter offering unfiltered analysis from Adam Feuerstein, a veteran reporter with decades of experience covering the intersection of Wall Street and biotechnology. It’s delivered on Thursday mornings, and STAT+ subscribers can sign up here.
Latest
STAT Plus: What to expect from UniQure’s upcoming Huntington’s gene therapy readout
STAT Plus: Abivax has still not been acquired. What’s going on?
STAT Plus: Alnylam’s heart drug troubles take center stage at a cardiology conference
STAT Plus: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
STAT Plus: One of the most consequential years for cancer treatment, ever
STAT Plus: Neurocrine Biosciences and the delicate balance of benefit and risk
STAT Plus: Biotech’s next big bet: A Tenax study of a heart failure treatment
All Coverage
